This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2011 Remove Pharmaceutical products Remove Safety Related Topics
Pharmaceutical manufacturing Prescription Pharma Patients FDA Leads Healthcare Medicine Insurance Consulting More Related Topics >
article thumbnail

Everything You Need to Know About Market Access in China

PM360

DECEMBER 20, 2023

Given China’s status as the world’s second most populous nation and an economic powerhouse, it represents both a monumental market opportunity and a dynamic arena of challenges for pharmaceutical products. Regulatory body – NMPA : all pharmaceutical products sold in the Chinese market need to be granted market authorization by NMPA.

Marketing 105
Marketing Insurance Medical Manufacturing 105
article thumbnail

Taming cardiovascular risk: the promise of LDL cholesterol lowering therapeutics

European Pharmaceutical Review

FEBRUARY 1, 2024

That will be our pivotal trial for not just LDL lowering, but also for safety in Phase III, because it is a very large trial. He also founded the Chicago Center for Clinical Research, which became the largest investigator site in the US and was acquired by Pharmaceutical Product Development in 1996.

Pharma 73
Pharma Patients Pharmaceutical Leads 73
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 8,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024